Home » News » Drug Sponsors » Merck and Sun sign pact

Merck and Sun sign pact

Tuesday, April 26, 2011

Merck and India-based Sun Pharmaceutical Industries have collaborated regarding rights to Merck’s diabetes drug Januvia, according to Pharma Times.

Merck and Sun have signed “an India-specific strategic partnership agreement” which states Sun will have the right to market, promote and distribute the dipeptidyl peptidase-4 inhibitor Januvia (sitagliptin) and Janumet (sitagliptin plus metformin), under different brand names.

K.G. Ananthakrishnan, managing director of Merck, Sharp & Dohme in India, indicated that the partnership will increase access to diabetic drugs in a country with “high disease burden of type 2 diabetes.”


Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!